Bio Rad Laboratories Stock Today
| BIO Stock | USD 246.40 3.25 1.30% |
PerformanceInsignificant
| Odds Of DistressLow
|
Bio Rad is selling at 246.40 as of the 20th of July 2025; that is 1.3 percent decrease since the beginning of the trading day. The stock's open price was 249.65. Bio Rad has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of April 2025 and ending today, the 20th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of January 1966 | Category Healthcare | Classification Health Care |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. The company has 22.14 M outstanding shares of which 890.79 K shares are currently shorted by investors with about 2.4 days to cover. More on Bio Rad Laboratories
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Norman Schwartz | ||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | ||||
| Old Names | [Biotest Aktiengesellschaft, Biotest Aktiengesellschaft, Biotest Aktiengesellschaft, Biotest Aktiengesellschaft, Biosearch S.A] | ||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, WSE WIG INDEX, SP Midcap 400, Warsaw WIG80 Index, Bucharest Plus Index, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Medical Devices, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal TestingCatholic | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBio Rad can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bio Rad's financial leverage. It provides some insight into what part of Bio Rad's total assets is financed by creditors.
| |||||
Bio Rad Laboratories (BIO) is traded on New York Stock Exchange in USA. It is located in 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 and employs 7,700 people. Bio Rad is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 6.76 B. Bio Rad Laboratories runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 22.14 M outstanding shares of which 890.79 K shares are currently shorted by investors with about 2.4 days to cover.
Bio Rad Laboratories has about 434.21 M in cash with 455.2 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 62.03.
Check Bio Rad Probability Of Bankruptcy
Ownership AllocationBio Rad holds a total of 22.14 Million outstanding shares. The majority of Bio Rad Laboratories outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bio Rad Laboratories to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bio Rad. Please pay attention to any change in the institutional holdings of Bio Rad Laboratories as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million twenty-three thousand eight hundred fifteen invesors are currently shorting Bio Rad expressing very little confidence in its future performance.
Check Bio Ownership Details
Bio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Asset Mgmt Americas Inc | 2025-03-31 | 382.8 K | |
| First Pacific Advisors, Lp | 2025-03-31 | 372.6 K | |
| Geode Capital Management, Llc | 2025-03-31 | 342.9 K | |
| Millennium Management Llc | 2025-03-31 | 336.1 K | |
| Southeastern Asset Management Inc | 2025-03-31 | 323.8 K | |
| Parnassus Investments Llc | 2025-03-31 | 318.1 K | |
| Mawer Investment Management Ltd | 2025-03-31 | 294.9 K | |
| Thompson, Siegel & Walmsley Llc | 2025-03-31 | 279.5 K | |
| Select Equity Group Lp | 2025-03-31 | 265.2 K | |
| Blackrock Inc | 2025-03-31 | 2 M | |
| Vanguard Group Inc | 2025-03-31 | 1.9 M |
Bio Rad Historical Income Statement
Bio Stock Against Markets
Bio Rad Corporate Directors
| Jeffrey Edwards | Independent Director | Profile | |
| Tania DeVilliers | Corporate Director | Profile | |
| Arnold Pinkston | Independent Director | Profile | |
| Alice Schwartz | Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Earnings Share (76.53) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.